Novo Nordisk reported a decline in adjusted sales and operating profit for Q1 2026, yet its obesity care segment, particularly the Wegovy pill, showed strong growth and outperformed competitors like Eli Lilly. The company benefits from patent protection for key drugs Ozempic and Wegovy until 2031-2032 in major markets, reducing near-term generic competition risks. Analysts see Novo Nordisk as undervalued with significant upside potential based on discounted cash flow models, supporting a strong buy recommendation despite recent underperformance and challenging guidance for 2026. This outlook is underpinned by the company's long-term growth prospects and competitive advantages.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
